Trial reportGynecologic oncology2020
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.
Trial report in Gynecologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02721732 (Phase II Study for the Evaluation of Efficacy of Pembrolizumab), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- A comprehensive bibliometric analysis (2000-2022) on the mapping of knowledge regarding immunotherapeutic treatments for advanced, recurrent, or metastatic cervical cancer.Frontiers in pharmacology · 2024Pooled it
- Recent progress and therapeutic strategies in the treatment of cervical neuroendocrine neoplasms (Review).International journal of molecular medicine · 2026Review
- Pembrolizumab-based systemic therapy associated with opportunities for subsequent local treatment in advanced or recurrent neuroendocrine carcinoma of the cervix: a five-case series.Gynecologic oncology reports · 2026Article
- Prolonged disease-free survival with immunotherapy combined with chemotherapy in a patient with advanced stage large cell neuroendocrine carcinoma of the uterus.Gynecologic oncology reports · 2026Article
- Complete remission of small cell neuroendocrine carcinoma of the cervix treated with chemotherapy of paclitaxel, carboplatin, bevacizumab and pembrolizumab: A case report.Gynecologic oncology reports · 2026Article
- Real-world safety and efficacy of immune checkpoint inhibitors in Japanese patients with persistent, recurrent, or metastatic cervical cancer: a multicenter prospective and retrospective study.International journal of clinical oncology · 2026Observational
- Case Report: Intramyometrial uterine large-cell neuroendocrine carcinoma mimicking adenomyosis and leiomyomas with rapid fatal relapse.Frontiers in oncology · 2026Article
- Article
- Clinical outcomes of neuroendocrine carcinoma of the cervix: Retrospective review from a large academic cancer centre.Gynecologic oncology reports · 2025Article
- Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab.Radiology case reports · 2025Article
- Single-cell RNA sequencing reveals tumor heterogeneity in small cell neuroendocrine cervical carcinoma.Communications biology · 2025Article
- Advances in cervical cancer: current insights and future directions.Cancer communications (London, England) · 2025Review
- Article
- Pan-Canadian Analysis of Practice Patterns in Small Cell Carcinoma of the Cervix: Insights from a Multidisciplinary Survey.Current oncology (Toronto, Ont.) · 2024Article
- Advancements in the Understanding of Small-Cell Neuroendocrine Cervical Cancer: Where We Stand and What Lies Ahead.Journal of personalized medicine · 2024Review
- Spatial profiling reveals tissue-specific neuro-immune interactions in gastroenteropancreatic neuroendocrine tumors.The Journal of pathology · 2024Article
- State of the art of cervical cancer treatment in rare histologies.Frontiers in oncology · 2024Review
- Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives.Journal of clinical medicine · 2023Review
- Review
- Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review.Clinical genitourinary cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo investigate the efficacy and safety of pembrolizumab in women with recurrent small cell neuroendocrine tumors of the lower genital tract.
methodsWe conducted an open-label, investigator-initiated phase II basket trial of pembrolizumab 200 mg intravenously every 3 weeks in patients with rare tumors (ClinicalTrials.gov: NCT02721732). The trial had prespecified cohorts, including small cell malignancies of extrapulmonary origin. Eligibility criteria included disease progression during standard treatment in the 6 months before study enrollment. Patients were enrolled from February 2017 to February 2019. The primary endpoint was the proportion of patients alive without progression at 27 weeks. Response to pembrolizumab was evaluated every 9 weeks (3 cycles) with radiographic imaging.
resultsSeven women with gynecologic extrapulmonary small cell carcinoma were enrolled, 6 with cervical and 1 with vulvar carcinoma. No patient was progression free at 27 weeks. At first radiologic assessment, 1 patient had stable disease, while 6 had progression. The single patient with stable disease at 6 weeks had disease progression at 14 weeks. The median progression-free interval was 2.1 months (range 0.8-3.3 months). Severe treatment-related adverse events (≥grade 3) were seen in 2 of 7 patients (29%); 1 patient had grade 3 asymptomatic elevation of serum alkaline phosphatase, and 1 had grade 3 asymptomatic elevation of serum alanine aminotransferase.
conclusionsPembrolizumab alone showed minimal activity in women with recurrent small cell neuroendocrine tumors of the lower genital tract. Treatment was well tolerated in the majority of study participants, and the rate of severe adverse events was low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.